Abstract
Background
Manifestations of thyroid-associated ophthalmopathy (TAO) vary greatly. Few tools and indicators are available to assess TAO, restricting personalized diagnosis and treatment.
Aim
To identify an aptamer targeting thyroid-stimulating hormone receptor (TSHR) and utilize this aptamer to evaluate clinical activity in patients with TAO.
Methods
An aptamer targeting TSHR was developed by exponential enrichment and systematic evaluation of TSHR ligands. After truncation and optimization, the affinity, equilibrium dissociation constant, and serum stability of this aptamer were evaluated. The affinity of the TSHR-targeting aptamer to isolated fibrocytes was assessed, as was aptamer internalization by fibrocytes. The mechanism of binding was determined by molecular docking. The correlation between disease manifestations and the percentage of TSHR-positive cells was assessed by correlation analysis.
Results
The aptamer TSHR-21-42 was developed to bind to TSHR, with the equilibrium dissociation constant being 71.46 Kd. Isolated fibrocytes were shown to bind TSHR-21-42 through TSHR, with its affinity maintained at various temperatures and ion concentrations. TSHR-21-42 could compete with anti-TSHR antibody, both for binding site to TSHR and uptake by cells after binding. In addition, TSHR-21-42 could bind to leukocytes in peripheral blood, with this binding differing in patients with TAO and healthy control subjects. The percentage of TSHR-positive monocytes, as determined by binding of TSHR-21-42, correlated positively with clinical activity score in patients with TAO, indicating that TSHR-21-42 binding could assess the severity of TAO.
Conclusion
This aptamer targeting TSHR may be used to objectively assess disease activity in patients with TAO, by evaluating the percentages of TSHR positive cells in peripheral blood.
Abbreviations
BSA, Bovine serum albumin; CAS, Clinical activity scores; EUGOGO, European Group on Graves’ orbitopathy; GD, Graves’ disease; HAS, Human serum albumin; PBMC, Peripheral blood mononuclear cells; SPR, Surface plasmon resonance; TAO, Thyroid-associated ophthalmopathy.
TSHR, Thyroid-stimulating hormone receptor; WBC, White blood cells.
Data Sharing Statement
The data that support the findings of this study are available from the corresponding author, WX, upon reasonable request.
Ethics Approval and Consent to Participate
The study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of The Third Xiangya Hospital of Central South University (NO: kuai 1 23004). Written informed consent was obtained from each subject.
Disclosure
The authors declare that they have no competing interests in this work.